The role of vascular endothelial growth factor (VEGF) signaling in cancer is not only well known in the context of angiogenesis but also important in the functional regulation of tumor cells. Autocrine VEGF signaling mediated by its co-receptors called neuropilins (NRPs) appears to be essential for sustaining the proliferation and survival of cancer stem cells (CSCs), which are implicated in mediating tumor growth, progression, and drug resistance. Therefore, understanding the mechanisms involved in VEGF-mediated support of CSCs is critical to successfully treating cancer patients. The expression of the Hippo effector TAZ is associated with breast CSCs and confers stem cell-like properties. We found that VEGF-NRP2 signaling contributed to the activation of TAZ in various breast cancer cells, which mediated a positive feedback loop that promoted mammosphere formation. VEGF-NRP2 signaling activated the GTPase Rac1, which inhibited the Hippo kinase LATS, thus leading to TAZ activity. In a complex with the transcription factor TEAD, TAZ then bound and repressed the promoter of the gene encoding the Rac GTPase-activating protein (Rac GAP) 2-chimaerin. By activating GTP hydrolysis, Rac GAPs effectively turn off Rac signaling; hence, the TAZ-mediated repression of 2-chimaerin resulted in sustained Rac1 activity in CSCs. Depletion of 2-chimaerin in non-CSCs increased Rac1 activity, TAZ abundance, and mammosphere formation. Analysis of a breast cancer patient database revealed an inverse correlation between 2-chimaerin and TAZ expression in tumors. Our findings highlight an unexpected role for 2-chimaerin in a feed-forward loop of TAZ activation and the acquisition of CSC properties.
INTRODUCTION
Vascular endothelial growth factor (VEGF) was originally character ized as a protein that promotes endothelial growth (1) and increa ses vascular permeability (2) . For these and other reasons, it was pre sumed that the role of VEGF in cancer was limited to angiogenesis (1, (3) (4) (5) . It is evident now, however, that there are angiogenesis independent functions of VEGF in cancer that are mediated by spe cific receptors. Tumor cells express VEGF receptor tyrosine kinases (VEGFR1 and VEGFR2) and neuropilins (NRPs), another family of VEGF receptors. NRP1 and NRP2 were identified initially as neuro nal receptors for semaphorins, which are axon guidance factors that function primarily in the developing nervous system (6) . The find ing that NRPs can also function as VEGF receptors and that they are expressed on endothelial and tumor cells launched studies aimed at understanding their contribution to angiogenesis and tumor biolo gy (7) . NRPs have the ability to interact with and modulate the func tion of VEGFR1 and VEGFR2, as well as other receptors (8) (9) (10) . There is also evidence that NRPs are valid targets for therapeutic inhibition of angiogenesis and cancer (11) (12) (13) (14) .
A surge of evidence has implicated autocrine VEGF signaling mediated by NRPs in the function of cancer stem cells (CSCs), a sub population of cells that function in tumor initiation, the differenti ation of multilineage cancer cell hierarchies, therapy resistance, and metastasis (12, (15) (16) (17) (18) (19) (20) (21) . These observations have led to intense in vestigation into the mechanisms by which VEGF sustains CSCs and how these processes can be exploited therapeutically. Previously, we reported that NRP2 is highly expressed in breast CSCs and that VEGFNRP2 signaling contributes to breast tumor initiation (22) . A key issue that emerges from these findings is the mechanism by which VEGFNRP2 signaling contributes to the function of CSCs. In pursuit of this issue, we were intrigued by reports that the Hippo pathway transducer TAZ confers stem cell properties and contrib utes to breast tumorigenesis, especially in highgrade tumors, which are distinguished by high NRP2 expression and VEGFNRP2 sig naling activity (22) . Moreover, TAZ expression in breast cancer cor relates with tumor grade (23) , and highgrade tumors harbor a higher frequency of CSCs than do lowergrade tumors (24) . Mechanistic studies have shown that TAZ can induce an epithelial to mesen chymal transition (EMT) in mammary epithelial cells (25) , a process that can increase stem cell properties (26) . Moreover, TAZ is neces sary for the selfrenewal of CSCs (23) . In contrast, the role of another Hippo pathway effector YAP in breast cancer is less clear, and its expression does not correlate with clinical outcome in breast cancer patients (27) .
The Hippo pathway consists of core kinases and regulatory mol ecules that facilitate TAZ phosphorylation, cytoplasmic retention, and inactivation (28) (29) (30) . For this reason, identifying upstream recep tors that disrupt Hippo signaling and, consequently, enhance TAZ activity is critical for understanding how these effectors contribute to the function of CSCs. Here, we discovered that VEGFNRP2 sig naling contributes to increased TAZ activity by a Rac1dependent, feedforward mechanism.
RESULTS

VEGF-NRP2 signaling contributes to TAZ activation
Initially, we assessed the contribution of VEGFNRP2 signaling to TAZ activation. For this purpose, we used an inducible system to transform MCF10A cells with Src, which generates a population of CD44 high /CD24 low cells with CSC properties (31) . This population is actually composed of distinct epithelial and mesenchymal popula tions (which we refer to herein as EPTH and MES, respectively) that differ in TAZ activity and tumorinitiating potential. The MES pop ulation has enhanced TAZ activity, selfrenewal potential, and tumor initiating capability compared to the EPTH population (32) . MES cells express increased amounts of VEGF and NRP2 compared to EPTH cells and are dependent on VEGFNRP2 signaling for selfrenewal (33) . Expression of either NRP2 (Fig. 1A) or VEGF (Fig. 1B) was diminished in MES cells using short hairpin RNAs (shRNAs), which resulted in decreased TAZ abundance compared to control cells, as assessed by immunoblotting (Fig. 1, A and B) . As reported previously, TAZ abundance is an indicator of its activation status (34, 35) , as is its nuclear localization. For this latter reason, we compared TAZ localization in control cells to VEGF and NRP2 depleted cells by immunofluorescence ( Fig. 1C and  fig. S1A ). TAZ was localized primarily in the nucleus in control MES cells ( Fig. 1C and fig. S1A ). In contrast, little, if any, TAZ was detected in VEGF and NRP2depleted cells, which is consistent with our immunoblotting data ( Fig. 1, A and B) . The TAZ that was detected in VEGFdepleted cells was localized in the cytoplasm (Fig. 1C and fig. S1A ).
Depletion of NRP2 in MES cells also reduced the mRNA expres sion of the TAZ target genes CTGF and CYR61 (Fig. 1D) . To sub stantiate the data obtained with shRNAs, we treated MES cells with a functionblocking NRP2 antibody (11) and observed a concentration dependent decrease in TAZ abundance (Fig. 1E) . Although similar results were observed for YAP ( fig. S1 , B and C), we focused subse quent experiments on TAZ because convincing data correlating YAP expression and clinical parameters in breast cancer are lacking (27) .
We extended this analysis to MDAMB231 cells because they exhibit mesenchymal properties and highly express VEGF and NRP2 (33) . Similar to MES cells, NRP2 depletion reduced the abundance of TAZ, as well as TAZ target genes (Fig. 1, F and G), suggesting that NRP2 affects TAZmediated transcription. TAZ regulates gene expression by associating with the TEAD family of transcription factors (36) , which infers that NRP2 should affect TEAD transcriptional activity. The activity of a TEAD luciferase reporter was reduced significantly in MDAMB231 cells with diminished NRP2 expression compared to control cells (Fig. 1H ).
Rac1 facilitates VEGF-NRP2-mediated activation of TAZ
To investigate the mechanism by which VEGFNRP2 signaling ac tivates TAZ, we focused on Rac1 for several reasons. This guanosine triphosphatase (GTPase) is a major effector of NRP/plexin signaling in neurons (37, 38) , and it has been implicated in VEGF signaling in endothelial cells (39, 40) . Moreover, Rac1 has also been implicated in TAZ activation (35, (41) (42) (43) . We observed that depleting VEGF expression or treating MES cells with the NRP2 function blocking antibody resulted in a substantial decrease in Rac1 activity (Fig. 2, A  and B) . Similar results were obtained in MDAMB231 cells (Fig. 2C) . Conversely, stimulating MDAMB231 cells with VEGF resulted in an increase in Rac1 activity (Fig. 2D ).
An important issue is whether VEGFRs contribute to Rac1 acti vation in breast cancer cells. Treatment of MDAMB231 cells with the VEGFR inhibitors pazopanib and sunitinib in the presence of VEGF did not decrease Rac1 activity compared to VEGF alone ( fig. S2 ), suggesting that VEGFNRP2-mediated activation of Rac1 is VEGFR independent. This result is not surprising because we reported pre viously that MDAMB231 and other breast cancer cell lines express very low amounts of VEGFRs (44) . In contrast, VEGFNRP2-mediated Rac1 activation appears to be focal adhesion kinase (FAK)-dependent, because the FAK inhibitor FAK14 significantly decreased Rac1 activity in MES cells (Fig. 2E ). This result is consistent with previous findings that FAK is a downstream effector of VEGFNRP2 signaling (22) , and it has been implicated in Rac1 activation (45) (46) (47) , as well as Hippo pathway regulation (48, 49) .
The results described above prompted us to evaluate whether VEGFNRP2 signals through Rac1 to promote TAZ activation. On the basis of our finding that depletion of NRP2 in MDAMB231 cells decreased the expression of TAZ target genes (Fig. 1G) , we found that expression of a constitutively active Rac1 (Rac1V12) in these cells rescued their expression (Fig. 2F) . This result provides evidence that the VEGFNRP2Rac1 axis contributes to TAZ activation. Subsequent ly, we assessed the role of Rac1 inhibition on mam mosphere formation in MES cells and observed decreased mammosphere formation upon treatment with the Rac inhibitors EHT1864 and NSC23766 (Fig. 2G) .
We next sought to investigate the mechanism by which VEGF NRP2-mediated regulation of Rac1 contributes to TAZ activation. We focused on the LATS tumor suppressor kinases because they phosphorylate TAZ directly at the Ser 89 position and promote its cytoplasmic retention and degradation when phosphorylated and activated on their hydrophobic motifs (Thr 1079 in LATS1 and Thr 1041 in LATS2) (25, 50, 51) . Moreover, LATS can be regulated by Rac1 (35, 41, 42 ) TAZ and a concomitant decrease in TAZ abundance (Fig. 3A) . It also increased the abun dance of pThr 1079 LATS1 and decreased TAZ abundance as early as 15 min after treatment, and this pattern persisted for up to 6 hours (Fig. 3B) . Expression of dominantnegative N17 Rac1 also decreased TAZ abundance in MES cells (Fig. 3C) . Similar results were ob tained with the NRP2 functionblocking antibody (Fig. 3D ). NRP2 knockdown in MDAMB231 cells also increased the abundance of pSer 89 TAZ and pThr 1079 LATS1 and decreased the abundance of TAZ (Fig. 3, E fig. S3A ).
Given the importance of TAZ in promoting CSC properties (23), we hypothesized that VEGFNRP2Rac1-mediated LATS inhibition is a critical upstream regulator of TAZmediated mammosphere forma tion. Depletion of NRP2 in MDAMB231 cells significantly reduced mammosphere formation, which was partially rescued by expression of wildtype TAZ (Fig. 3G and fig. S4 ). Expression of S89A TAZ, which is resistant to LATSmediated phosphorylation at that site, res cued mammosphere formation significantly more than did expression of wildtype TAZ (Fig. 3G and fig. S4 ). Similar results were obtained by VEGF depletion in MES cells (Fig. 3H) . These results indicate that the wildtype TAZ ectopically expressed is subject to regulation by upstream VEGFNRP2 signaling, but that the S89A TAZ mutant is not. Together, these data provide functional evidence that VEGFNRP2Rac1 promotes a TAZdependent stemlike phenotype through inhibition of LATS mediated phosphorylation of TAZ at Ser 89 .
To gain insight into the mechanism by which VEGFNRP2Rac1 signaling inhibits LATS activity, we postulated that this signaling regulates Merlin, the protein product of the neurofibromatosis type 2 (NF2) gene, because phosphorylation of Merlin on Ser 518 by PAK is inhibitory (52) (53) (54) . Moreover, Merlin phosphorylation in hibits LATS phosphorylation (55) . These findings are relevant be cause PAK is a Racactivated kinase (56) . Following these observa tions, we found that either Rac inhibition or NRP2 depletion in MES cells reduced the abundance of Ser 518 phosphorylated Merlin ( fig. S3 , B and C). 
VEGF-NRP2 signaling represses the Rac GAP 2-chimaerin
Rac1 cycles from guanosine triphosphate (GTP)-bound active states to guanosine diphosphate (GDP)-bound inactive states, which, in large part, is regulated by the expression of guanine nucleotide exchange factors (GEFs) and GTPaseactivating proteins (GAPs). Therefore, we profiled the expression of known Rac GEFs and GAPs in EPTH and MES cells (Table 1) . Notably, we observed that the expression of the Rac GAP 2chimaerin at the mRNA level (CHN2, hereafter β2-chimaerin) was markedly reduced in MES cells compared to EPTH cells (Table 1) , which we verified by immunoblotting (Fig. 4A ). 2chimaerin is a Racspecific GAP that has been implicated as a tumor suppressor in breast cancer (57) (58) (59) (60) (61) . Given that 2chimaerin abun dance is reduced in MES cells and these cells highly express VEGF and NRP2 (33), we assessed whether VEGFNRP2 signaling repressed 2chimaerin expression. We observed that NRP2 depletion in creased 2chimaerin abundance at both the mRNA and protein Representative blots are shown; data are means ± SEM of three biological replicates of the 6-hour condition. DMSO, dimethyl sulfoxide. (F) NRP2 expression was diminished in MDA-MB-231 cells that were then transfected with constitutively active Rac1 (V12 Rac1-GST). GST abundance was quantified by immunoblotting (blots, left), and mRNA expression of the indicated TAZ target genes was quantified by qPCR (graph, right). Data are means ± SEM of three biological replicates. (G) MES cells were treated with Rac inhibitor (50 M EHT1864 or NSC23766) and assayed for self-renewal by serial passage mammosphere formation. P1, passage 1; P2, passage 2. Data are means ± SEM of three biological replicates. *P ≤ 0.05 by two-tailed t test.
level in MES cells (Fig. 4, B and C) . Treatment of MES cells with the NRP2 functionblocking antibody also increased 2 chimaerin abun dance (Fig. 4D ). These observations provide evidence that VEGF NRP2 signaling represses 2chimaerin expression.
TAZ activates Rac1 by repressing 2-chimaerin through a TEAD-dependent mechanism
On the basis of our observation that VEGFNRP2 signaling activates TAZ and represses 2chimaerin, we assessed the possibility that TAZ represses 2chimaerin. This possibility is supported by studies demonstrating that TAZ can function in transcriptional repression (62, 63) . Depletion of TAZ in MES cells increased both mRNA and protein abundance of β2chimaerin and consequently decreased Rac1 acti v ity (Fig. 5, A to C) . TAZ knock down in MDAMB435 cells (Fig. 5D ) and MDAMB231 cells (Fig. 5E ) also increased 2-chimaerin mRNA expression. Conversely, TAZ over expression repressed 2-chimaerin mRNA expression in MDAMB231 cells (Fig. 5F ). Given our observations that Rac1 activates TAZ (Fig. 3) and that TAZ represses 2 chimaerin expression, we inhibited Rac1 in MES cells using EHT1864 and observed an increase in the expression of 2-chimaerin mRNA (Fig. 5G) . These results provide evidence that VEGF NRP2Rac1-mediated TAZ activation maintains increased Rac1 activity by repressing 2chimaerin in a positive feedback loop. TAZmediated transcriptional repression is dependent on the TEAD1-4 family of transcription factors (62, 63) . TEAD4, in particular, is expressed at relatively high levels in breast cancer, especially triple negative breast cancer (64, 65) . Given this information, we initially searched the encyclopedia of DNA elements (ENCODE) for TEAD4 chromatin immunoprecipitation sequencing (ChIPseq) data sets and found four cell types [h1human embryonic stem cells (hESCs), HCT116 colon cancer cells, Ishikawa endometrial adenocarcinoma cells, and SKNSH neuroblastoma cells], where TEAD4 bound to the promoter region of the 2-chimaerin gene (Fig. 6A) . Specifically, a con served peak was observed near position 29229000 (chr7) in all of the cell types. These findings are significant because they demonstrate di rect binding of TEAD4 to the 2chimaerin promoter. In addition, h1 hESCs, HCT116, Ishikawa, and SKNSH cells have enhanced TAZ/ TEAD activity (66, 67) . To validate the ENCODE data in our model system, we performed ChIP in MES cells using antibodies specific for TEAD4 and TAZ. The results verify that TEAD4 and TAZ are recruited to the genomic region in the 2chimaerin promoter identified in ENCODE (Fig. 6B) . On the basis of these data, we depleted TEAD1/3/4 expression in MES cells and observed an increase in the mRNA and pro tein abundance of 2chimaerin (Fig. 6, C and D) and a decrease in Rac1 activity (Fig. 6E) , consistent with our TAZ knockdown results (Fig. 5,  A to C) . Similarly, expression of dominant negative TEAD4 in MDA MB231 cells increased 2-chimaerin mRNA expression (Fig. 6F) .
2-chimaerin repression contributes to enhanced TAZ activity
An important question that arises from the data thus far is whether 2chimaerin repression has a causal role in TAZ activation. Expres sion of 2chimaerin in MDAMB231 cells decreased Rac1 activity, as well as the abundance of TAZ itself (Fig. 7A ) and TAZ target genes (Fig. 7B) . Conversely, 2chimaerin knockdown in EPTH cells in creased Rac1 activity, TAZ abundance (Fig. 7C) , and TAZ target genes (Fig. 7D) . Notably, 2chimaerin-depleted EPTH cells exhibited in creased mammosphere formation compared to control EPTH cells (Fig. 7E) . Expression of 2chimaerin also reduced TAZ mediated, but not S89A TAZmediated, mammosphere formation in MDA MB231 cells (Fig. 7F) , providing further evidence that Rac1 inhibi tion of LATS contributes to TAZ activation and CSC properties.
These in vitro data indicating an inverse causal relationship between 2chimaerin and TAZ and a positive causal relationship between VEGFNRP2 and TAZ were substantiated by analysis of their ex pression in invasive breast carcinomas in The Cancer Genome Atlas (TCGA) database obtained from cBioPortal ( Fig. 7G) (68, 69) . The expression of TAZ and 2chimaerin was inversely correlated. In con trast, the expression of TAZ correlated with that of VEGF and NRP2. An inverse correlation between TAZ and 2chimaerin was also detected in glioblastoma and colorectal adenocarcinoma samples in the TCGA. These findings are significant because both glioblastoma and colon cancer exhibit enhanced TAZ activity (66, 70, 71) . Last, TAZ and 2 chimaerin exhibited an inverse correlation in the CCLE obtained from cBioPortal (967 cell lines) (Fig. 7G) , which provides fur ther evidence of a repressive role (68, 69) . Our data indicate that TAZmediated re pression of 2chimaerin is associated with a mesenchymal phenotype. To substanti ate this conclusion, we analyzed a micro array (GSE48204) that used trans forming growth factor- (TGF)-treated NMuMG mammary epithelial cells to induce an EMT (72) . In support of our conclusion, we found that the EMT reduced 2chimaerin ex pression and increased expression of VEGF and NRP2, as well as TAZ target genes ( fig. S5 ). We also used cBioPortal to strat ify breast cancer patients in the TCGA database based on their expression of the estrogen receptor (ER), which is associ ated with an epithelial pheno type. Com parison of 2 chimaerin expression in the ERpositive (ER + ) and ER − subgroups re vealed that ER − patients have lower expression of 2 chimaerin compared to ER + patients (Fig. 7H ).
DISCUSSION
The results of this study establish a causal role for VEGFNRP2 signaling in sustain ing the activation of TAZ, a critical effec tor molecule of the Hippo pathway that contributes to breast tumorigenesis and is associated with aggressive, highgrade tu mors. An essential component of this mech anism is the repression of 2 chimaerin, a Rac GAP, by TAZ and the consequent acti vation of Rac1, resulting in a positive feed back loop driven by VEGF NRP2 signaling that sustains TAZ activation (Fig. 8) . These findings increase our understanding of autocrine VEGF signaling in tumor cells, and they substantiate the importance of Rac in the biology of CSCs and TAZ regulation. Our conclusion that repression of 2 chimaerin contributes to TAZ activation and selfrenewal indicates that this Rac GAP is an important gatekeeper that im pedes the acquisition of stem cell prop erties. On the basis of the hypothesis that breast CSCs are dedifferentiated and exhibit features of an EMT (26), this conclusion infers that repression of 2chimaerin is a consequence of the EMT and that its expression is associated with an epithelial pheno type. We uncovered that 2chimaerin is repressed by the TGF -induced EMT of mammary epithelial cells. We also demonstrated that ER + patients have higher 2 chimaerin expression compared to ER − patients. These observations contrast with the report that 2 chimaerin reduces Ecadherin levels in an in vitro overexpression system (60) . How ever, this report also demonstrated that low expression of 2 chimaerin is associated with reduced relapsefree survival of breast cancer pa tients, which supports our findings. Our results need to be discussed in the context of the report that NRP2 binds 2 chimaerin directly, and that semaphorin 3F-NRP2 sig naling reduces this association to activate 2chimaerin and regulate axonal pruning in the hippocampus (38) . Although 2 chimaerin and NRP2 exhibit an inverse expression pattern in breast cancer, we tested the hy pothesis that residual 2 chimaerin may be sequestered and inactivated by NRP2 as a mechanism of Rac1 regulation. How ever, we were unable to co immunopurify NRP2 with 2 chimaerin. This is not de finitive, but it does suggest that NRP2 reg ulation of 2 chimaerin differs in breast cancer cells and neurons. This difference may reflect the fact that different ligands (semaphorin 3F and VEGF) engage NRP2 in these cell types. It is also worth men tioning that we previously demonstrated that semaphorin 3A and VEGF compete for NRP binding in breast cancer cells and that these two ligands have opposite ef fects on the behavior of these cells (73) . Nonetheless, the existing data highlight an important causal effect of NRP2 on 2 chimaerin that is executed by distinct mechanisms.
A major conclusion of this study is that VEGFNRP2 signaling contributes to TAZ activation by a Rac1dependent mechanism. This role for Rac1 differs from its more es tablished role in regulating cell in vasion and migration in cancer, but it is consistent with other reports implicating Rac1 in the func tion of CSCs (74) (75) (76) , as well as in YAP/ TAZ activation (35, (41) (42) (43) . Our results on the ability of VEGFNRP2 signaling to in hibit LATS by a Rac1 dependent mech anism support these ob servations, and they identify a novel ligand receptor interac tion that can me diate this regulation. Fur thermore, our data suggest that the ability of Rac1 to inhibit LATS is mediated by its regulation of Merlin, which is an important organizer of the membrane cytoskeleton interface (52) (53) (54) (55) (77) (78) (79) . Al though we are not ruling out the possibility that VEGF NRP2 signaling may activate RhoA, which has also been implicated in YAP/TAZ acti vation (35, 41, (79) (80) (81) , we focused our at tention on Rac1 because 2chimaerin is Rac specific and does not have GAP activ ity against Rho (57, 58) .
Although many studies have implicated autocrine VEGF signaling in the function of CSCs (20) , its ability to contribute to HippoTAZ regulation provides a new di mension to our understanding of VEGF biology. While this manuscript was in review, however, it was reported that VEGF VEGFR2 signaling contributes to YAP/TAZ activation during developmental angiogenesis (82) . Our data support the role of VEGF in promoting YAP/TAZ activation, but the mechanism used by breast cancer cells is distinct because it appears to be dependent on VEGFNRP2 activation of FAKRac1 but independent of VEGFR. Moreover, our findings reveal a pivotal role for 2chimaerin as a repressive intermediary between VEGFNRP2 and TAZ activation. They also reinforce the hypothesis that targeting VEGFNRP sig naling is a viable therapeutic strategy for tumor cells that are depen dent on TAZ activation.
MATERIALS AND METHODS
Reagents and antibodies EHT1864 was purchased from Tocris, NSC23766 was purchased from Selleckchem, FAK14 was purchased from Sigma, sunitinib and pazopanib were purchased from LC Laboratories, human VEGFA165 was purchased from R&D Systems, and the functionblocking NRP2 antibody was provided by Genentech (11) . 
Constructs
The following lentiviral shRNA vectors were used: VEGF (TRCN0000003343, TRCN0000003344, and TRCN0000003345), NRP2 (TRCN0000063309, TRCN0000063312, and TRCN0000063310), −/low MCF10A ER SRC-transformed cells using flow cytometry has been previously described (33) . EPTH and MES cells were cultured as subclones for two to three passages and used for experiments. MDAMB231 and MDA MB435 cells were obtained from the American Type Culture Collec tion. All experiments were performed at a cell density of 25 to 35%.
Transfection and siRNA knockdown
For overexpression, plasmids were transfected using Lipofectamine 2000 (Thermo Fisher Scientific). Cells were processed for immunoblotting, qPCR, or mammosphere formation about 24 hours after transfection. For LATS1/2 small interfering RNA (siRNA) knockdown, MDAMB 231 cells were transfected using DharmaFect 4 (Dharmacon). Cells were processed for immunoblotting 48 hours after transfection. LATS1/2 siRNA has been previously described (32) .
Mammosphere assay
Cells were plated in UltraLow attachment sixwell plates in Dulbecco's modified Eagle's medium/F12 medium supplemented with B27, epi dermal growth factor, and fibroblast growth factor as previously de scribed (33) . For serial passaging, mammospheres were pelleted and dissociated with 0.05% trypsin for 15 min at 37°C to obtain single cells. These cells were washed in 1× phosphatebuffered saline (PBS), counted, and replated in UltraLow attachment sixwell plates.
Immunoblotting
Cells were washed in 1× PBS and scraped on ice in radioimmuno precipitation assay buffer with EDTA and EGTA (BP115DG, Boston BioProducts) supplemented with protease and phosphatase inhibitors (Pierce, #88669). Laemmli 6× SDS sample buffer (BP111R, Boston BioProducts) was added to each sample, and the protein lysate was boiled for 10 min and separated using SDS-polyacrylamide gel electro phoresis. Rac activity was assessed using a GST fusion protein con taining the Rac/Cdc42binding domain of PAK (PBD) as previously described (21, 83) . Luciferase reporter assay TEAD transcriptional activity was assessed using a luciferase reporter construct (8xGTIIC, Addgene #34615) with the DualLuciferase Re porter Assay System (#E2940, Promega). About 24 hours after trans fection, luciferase activity was measured as the average ratio of firefly to Renilla luciferase.
Real-time qPCR RNA extraction was accomplished using an RNA isolation kit (BS88133, Bio Basic Inc.), and cDNAs were produced using a qScript cDNA syn thesis kit (#95047, Quantabio). SYBR Green (Applied Biosystems) was used as the qPCR master mix. Experiments were performed in trip licate and normalized to glyceraldehyde3phosphate dehydrogenase (GAPDH). qPCR primer sequences were obtained from the Massachusetts General Hospital/Harvard Medical School PrimerBank (http://pga.mgh. harvard.edu/primerbank/).
Chromatin immunoprecipitation
ChIP was performed using a ChIPIT Express Chromatin Immuno precipitation kit (Active Motif). Antibodies used were TEAD4 (NG2, Santa Cruz Biotechnology) and TAZ (70148S, Cell Signaling Tech nology). The following qPCR primer sequence was used to amplify the region of the TEAD4 peak in the 2chimaerin promoter iden tified in ENCODE: primers 5′GCTTACAGCTGGCTTCACTT3′ (forward) 5′GGCCGAGAGAGAGAGAGTTT3′ (reverse).
Immunofluorescence confocal microscopy TAZ localization was performed by fixing cells with paraformalde hyde (4%) and permeabilizing them with Triton X100 (0.1%) as described (23, 32) . Cells were blocked with 1% bovine serum albu min and horse serum (2.5%) and incubated with TAZ antibody (1:100 dilution; sc48805, Santa Cruz Biotechnology) overnight at 4°C. Subsequently, cells were washed with 1× PBS and incubated with fluorochromeconjugated secondary antibodies. Images were captured at ×20 magnification using a confocal microscope (Zeiss).
ENCODE data analysis
ENCODE TEAD4binding signals were downloaded from www. encodeproject.org in bigwig format. The coverages of duplicate samples were pooled and then plotted along the promoter region of the 2-chimaerin (CHN2) gene. cBioPortal analysis cBioPortal (www.cbioportal.org) was used to compare the mRNA ex pression (RNA Seq V2 RSEM) of TAZ, VEGFA, NRP2, and 2 chimaerin using the TCGA invasive breast carcinoma provisional data set (68, 69) . In addition, the mRNA expression (RNA Seq V2 RSEM) of TAZ and 2-chimaerin was compared in the TCGA glioblastoma pro visional data set and the TCGA colorectal adenocar cinoma Nature 2012 data set. The CCLE (Novartis/Broad, Nature 2012) was used to compare the expression of TAZ and 2-chimaerin across various cell lines using the mRNA expression zscores microarray. To determine whether the expression of two genes is inversely correlated, we per formed the mutual exclusivity analysis with a zscore threshold of ±1.5 as expressed, and calculated the log odds ratio between the two genes and P value using Fisher's exact t test. In addition, we stratified breast cancer patients in the TCGA Cell 2015 database based on their ER sta tus, and compared 2chimaerin expression in the ER + and ER − sub groups using Welch t test.
Microarray data analysis
The microarray data set from Gene Expression Omnibus (GEO) (GSE48204) (72) was downloaded using the Bioconductor package GEOquery (version 2.41.0). Moderated t test was used to identify differentially expressed genes between TGF-induced EMT cells and NMuMG cells treated with vehicle. Genes with an adjusted P value of ≤0.05 using BenjaminiHochberg method were consid ered significant (84) .
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/11/528/eaao6897/DC1 Fig. S1 . VEGF-NRP2 signaling contributes to YAP activation. Fig. S2 . VEGF-NRP2 activation of Rac1 is independent of VEGFR. Fig. S3 . VEGF-NRP2-Rac1 regulation of Merlin phosphorylation (pSer 518 ) is LATS-dependent. Fig. S4 . Expression of wild-type and S89A TAZ constructs. Fig. S5 . 2-chimaerin is repressed by the EMT.
